Innovent Bio's latest monthly securities change report submitted on July 31, 2024 shows that the number of ordinary shares of the company remained unchanged in July, with a total of 5,000,000,000 shares, and the total amount of legal/registered capital was $50,000. At the same time, the issued shares (excluding treasury shares) increased from 1,628,413,570 shares at the end of the previous month to 1,629,278,889 shares, an increase of 865,319 shares. The increase was mainly due to the exercise of stock option plans, including pre-IPO share incentive plans and employee shareholding plans after the IPO. The total amount of funds obtained from exercising options this month was HKD 11,525,159.63. The report was submitted to the Hong Kong Exchanges and Clearing Limited by the joint company secretary Wang Yanju on August 6, 2024.

Innovent Bio's latest monthly securities change report submitted on July 31, 2024 shows that the number of ordinary shares of the company remained unchanged in July, with a total of 5,000,000,000 shares, and the total amount of legal/registered capital was $50,000. At the same time, the issued shares (excluding treasury shares) increased from 1,628,413,570 shares at the end of the previous month to 1,629,278,889 shares, an increase of 865,319 shares. The increase was mainly due to the exercise of stock option plans, including pre-IPO share incentive plans and employee shareholding plans after the IPO. The total amount of funds obtained from exercising options this month was HKD 11,525,159.63. The report was submitted to the Hong Kong Exchanges and Clearing Limited by the joint company secretary Wang Yanju on August 6, 2024.